Published Medical Literature

Surgery Type for Lung Cancer May Influence Later Opioid Use

Epigenetic Alterations and Tumor Mutational Burden in NSCLC

Does Early CT Screening for Lung Cancer Reduce Mortality?

Do Brain Metastases Affect Outcomes With Immunotherapy?

Can Salvage Treatment Improve Survival in Early-Stage Lung Cancer?

Impact of Neoadjuvant Erlotinib on Radical Resection Rate in Patients With NSCLC

Acquired Osimertinib Resistance in EGFR-Positive NSCLC

Does Baseline Steroid Use Impact Efficacy of Immunotherapy in Patients With NSCLC?

New Test May Help Risk Stratify Patients With NSCLC for Treatment

Osimertinib Treatment in T790M-Positive NSCLC With CNS Metastases

Should Cisplatin Accompany First-Line NSCLC Treatment in Elderly Patients?

Review Features Clinical Challenges of Personalized Treatment in NSCLC

ERBB Mutation as Predictive Biomarker for Afatinib Treatment in Lung Cancer

Is Ado-Trastuzumab Emtansine Active in HER2-Mutant Lung Cancer?

Addition of Biomarker Panel to Lung Cancer Screening: Can It Improve Detection of Disease?

Retrospective Analysis of Brain Metastases in Patients With Stage IV NSCLC

Does Prior Antibiotic Use Affect Treatment Outcomes in Lung Cancer?

Brigatinib Active in Patients With ALK-Positive Lung Cancer

Overall Survival Benefit of Crizotinib in Patients With ALK-Positive NSCLC

How Accurate Are Lung Cancer Risk Models for Selecting Ever-Smokers for Screening?

Screening for Intracranial Disease in Patients With Lung Cancer Versus Breast Cancer

ASTRO Updates Guideline for Palliative Radiation Therapy for Lung Cancer

Immune Stimulant in Combination With Nivolumab for Metastatic Lung Cancer

Efficacy of Immunotherapy for Lung Cancer: Does Gender Matter?

Risk of Brain Metastases in Patients With NSCLC

Updated ASTRO Guideline Focuses on Palliative Radiotherapy for Lung Cancer

Review Offers 2018 Roadmap for Treating Advanced Non–Small Cell Lung Cancer

Geographic Disparity Observed in Lung Cancer Deaths in Women

Hypoxia as Therapeutic Target in Non–Small Cell Lung Cancer

Durvalumab in Heavily Pretreated Patients With Advanced Lung Cancer

Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types

Long-Term Survival With Nivolumab in Pretreated Patients With Advanced Lung Cancer

Update on Genomic Testing for Patients With Lung Cancer

Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer

Risk of Second Primary Lung Cancer After Treatment of Primary Lung Tumor

ASCO Endorses Molecular Testing Guideline Update for TKI Treatment in Lung Cancer

Update on Treatment of Oligometastatic Lung Cancer

Targeted Next-Generation Sequencing for Predicting Treatment Response in Lung Cancer

Targeted Radiation vs. Surgery for Early-Stage Lung Cancer

Osimertinib in Treating CNS Metastases From Lung Cancer

Combination Therapy for Previously Untreated Advanced Lung Cancer

Chemoradiation Versus Radiation Alone in Elderly Patients With Lung Cancer

Effect of Pembrolizumab on Quality of Life for Patients With Advanced Lung Cancer

Radiosurgery vs. Whole-Brain Radiation for Brain Metastases in Patients With Lung Cancer

Should Bevacizumab Accompany Adjuvant Chemotherapy in Early-Stage NSCLC?

Osimertinib as First-line Treatment of EGFR-Mutant Advanced NSCLC

Long-Term Outcomes With Nivolumab vs. Docetaxel in Advanced Lung Cancer

Safety of Checkpoint Inhibitors Plus Radiotherapy for Metastatic Lung Cancer

Dacomitinib vs. Gefitinib in First-Line Treatment of EGFR Mutation–Positive NSCLC

Gefitinib Plus Chemotherapy in the IMPRESS Trial: Final Overall Survival

Does Adding Motesanib to Paclitaxel/Carboplatin Improve Outcomes in East Asian Patients With Lung Cancer?

Icotinib vs. Chemotherapy in EGFR-Positive Lung Adenocarcinoma

Dabrafenib and Trametinib in BRAF V600E–Mutant Metastatic NSCLC

Hair Repigmentation and Response to Immunotherapy for NSCLC

Consolidative Radiotherapy Prior to Chemotherapy for Limited Metastatic NSCLC

Are Immune-Related Adverse Events With Nivolumab Linked to Efficacy in NSCLC?

First-Line Treatment With Osimertinib in EGFR Mutation–Positive Advanced NSCLC

Pathologic Nodal Staging Quality and Survival Differences in Non–Small Cell Lung Cancer

Immunotherapy After Chemoradiotherapy for Stage III Lung Cancer

Adding First-Line Ipilimumab to Chemotherapy for Squamous NSCLC

Fat Intake and Risk of Lung Cancer

COPD Treatment Initiative for Patients With Lung Cancer

Frequency of Lung Cancer in Never-Smokers in the UK

Surfactant Protein D and Clinical Outcomes in Lung Cancer

Use of Supplemental Vitamin B and Risk of Lung Cancer

Comparing Chemotherapy Regimens With Gemcitabine and Cisplatin in Advanced NSCLC

Combination Therapy With Apatinib in Resistant NSCLC

Updated Molecular Analyses in NSCLC Patients Treated With Erlotinib

Driver Mutations and Therapy Selection for Lung Adenocarcinoma

Concurrent Chemotherapy and Proton Therapy in Advanced Lung Cancer

Robot-Assisted Thoracic Surgery for Lung Lobectomy in NSCLC

Brigatinib in Crizotinib-Refractory ALK-Positive Non–Small Cell Lung Cancer

Nivolumab in the First-Line Treatment of Advanced or Recurrent Lung Cancer

Atezolizumab in PD-L1–Selected Advanced Non–Small Cell Lung Cancer

Cost Analysis of Personalized vs Fixed Dosing of Pembrolizumab

Alectinib and CNS Response in Resistant ALK-Positive Disease

Alectinib vs Crizotinib in ALK-Positive NSCLC

Potential Biomarker in Lung Squamous Cell Carcinoma

Early-Phase Trial of Vaccine in NSCLC

Brigatinib in Patients With Crizotinib-Refractory ALK–Positive NSCLC

Local Ablative Therapy for Oligometastatic Lung Cancer

Addition of Selumetinib to Docetaxel in KRAS-Mutant Lung Cancer

Chromosome Instability: Potential Prognostic Predictor in Lung Cancer

Multikinase Inhibitors in RET-Rearranged NSCLC

A Population-Based Comparative Effectiveness Study of Chemoradiation Regimens and Sequences in Stage III NSCLC

Osimertinib or Platinum/Pemetrexed in EGFR T790M–Positive Lung Cancer

Impact of Reflex EGFR/ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous NSCLC

Proportion of Never-Smoker NSCLC Patients at Three Diverse Institutions

Atezolizumab vs Docetaxel in Patients With Previously Treated NSCLC (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial

Management Strategies for Adverse Events Associated With EGFR TKIs in NSCLC

Treatment of Stage IIIA NSCLC